Information Provided By:
Fly News Breaks for March 25, 2015
NEO
Mar 25, 2015 | 08:40 EDT
Roth Capital expects reimbursement rates for NeoGenomics' tests to rebound in 2H15, since the firm believes, based on data, that most labs are probably performing the tests below costs. The firm keeps a $7 price target and Buy rating on NeoGenomics.
News For NEO From the Last 2 Days
There are no results for your query NEO